DV
Dividend Vision

BCDA — Biocardia Inc

Biocardia Inc (BCDA)

Total return is -100.0% over the past 29.7 years, 1763.3 points behind SPY at 1663.3%. Its deepest 1-year drawdown was 66.1%.

BioCardia is a clinical-stage regenerative medicine company developing cellular and cell-derived therapies for cardiovascular and pulmonary diseases, with its lead product candidate CardiAMP in Phase III trials for ischemic heart failure and refractory angina. The company does not currently distribute dividends. BioCardia appeals to investors seeking exposure to early-stage biotech development rather than current income generation.

BCDA key facts

Asset type
Stock
Asset class
Equity
Inception date
11/13/1996
Last close
$0.97
Market cap
$12,291,478
Average volume
158400.0
Payment date
06/06/2019
Beta
0.437
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.85